Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
12 hedge funds and large institutions have $2.14M invested in Oncobiologics, Inc. Series B Warrant in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
9% more funds holding
Funds holding: 11 → 12 (+1)
37% less capital invested
Capital invested by funds: $3.4M → $2.14M (-$1.26M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$19.3K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.95K |
| 2 |
Millennium Management
New York
|
-$901 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $726K | +$2.79K | +3,621 | +0.4% |
|
|
PA
2
Perceptive Advisors
New York
| $518K | – | – | – |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $329K | – | – | – |
|
|
ACA
4
Avoro Capital Advisors
New York
| $184K | – | – | – |
|
5
Marshall Wace
London,
United Kingdom
| $99K | – | – | – |
|
|
PC
6
PointState Capital
New York
| $79K | – | – | – |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $76K | – | – | – |
|
|
JG
8
Jefferies Group
New York
| $63K | – | – | – |
|
|
9
Millennium Management
New York
| $33K | -$901 | -1,170 | -3% |
|
|
MIM
10
Monashee Investment Management
Boston,
Massachusetts
| $20K | +$19.3K | +25,000 | New |
|
11
Morgan Stanley
New York
| $7K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $3K | -$1.95K | -2,528 | -40% |
|
ONSIZ Hedge Fund Activity: Q4 2016 in Review
12 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q4 2016, worth a combined $2.14M — down 37% from $3.4M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ONSIZ positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $19.3K. The largest seller was UBS Group, cutting an estimated $1.95K.
- 12 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q4 2016, up from 11 in Q3 2016.
- Funds reported $2.14M of Oncobiologics, Inc. Series B Warrant stock for Q4 2016, down 37% quarter-over-quarter.
- 1 fund opened new Oncobiologics, Inc. Series B Warrant positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q4 2016 was Monashee Investment Management, an estimated $19.3K added.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q4 2016 was UBS Group, an estimated $1.95K sold.
Based on aggregated 13F filings for Q4 2016.